Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 22670442)

1.

[How I treat ... dyslipidemia according to the cardiovascular risk profile].

Descamps OS, Scheen AJ, De Backer G, Annemans L, Muls E; Belgian Atherosclerosis Society/Belgian Lipid Club.

Rev Med Liege. 2012 Apr;67(4):167-73. French.

PMID:
22670442
2.

[New European guidelines for the management of dyslipidaemia in cardiovascular prevention].

Descamps OS, De Backer G, Annemans L, Muls E, Scheen AJ; Belgian Atherosclerosis Society; Belgian Lipid Club.

Rev Med Liege. 2012 Mar;67(3):118-27. French.

PMID:
22611827
3.

[New european guidelines for dyslipidemia].

Riesen WF, Virgini V, Vogt B, Rodondi N.

Rev Med Suisse. 2012 Mar 7;8(331):525-6, 528-30. French.

PMID:
22471115
4.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
5.

Dyslipidemia therapy update: the importance of full lipid profile assessment.

Menown IB, Murtagh G, Maher V, Cooney MT, Graham IM, Tomkin G.

Adv Ther. 2009 Jul;26(7):711-8. doi: 10.1007/s12325-009-0052-3. Epub 2009 Jul 27. Review.

PMID:
19649582
6.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
8.

Pathogenesis and management of the dyslipidemia of the metabolic syndrome.

Raal FJ.

Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079. Review.

PMID:
19400742
9.

Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.

Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, Boudreau G; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group.

Arch Intern Med. 2007 Nov 26;167(21):2296-303.

PMID:
18039987
10.

Risk of cardiovascular events in patients at optimal values for combined lipid parameters.

Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ.

Curr Med Res Opin. 2007 Mar;23(3):553-63.

PMID:
17357251
11.

Atherogenic dyslipidemia.

Hayden MR.

J Cardiometab Syndr. 2006 Summer;1(3):166-7. No abstract available.

PMID:
17679821
12.

Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.

Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E.

Arch Cardiovasc Dis. 2009 Jan;102(1):43-50. doi: 10.1016/j.acvd.2008.06.021. Epub 2009 Jan 25.

13.

Cardiovascular disease and dyslipidemia: beyond LDL.

Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M, Laufs U.

Curr Pharm Des. 2011;17(9):861-70. Review.

PMID:
21418031
14.

[New European clinical guidelines on dyslipidemias].

Matikainen N, Taskinen MR.

Duodecim. 2012;128(16):1651-62. Finnish.

PMID:
23025148
15.

The new strategy for modulating dyslipidemia: consideration from updated understanding on high-density lipoprotein.

Wen C, Xu H.

Chin J Integr Med. 2011 Jun;17(6):467-70. doi: 10.1007/s11655-011-0632-3. Epub 2011 Mar 4.

PMID:
21373982
16.

Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.

Jaussi A, Noll G, Meier B, Darioli R.

Eur J Cardiovasc Prev Rehabil. 2010 Jun;17(3):363-72. doi: 10.1097/HJR.0b013e328333c1d9.

PMID:
20168234
17.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
18.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
19.

Optimal lipid targets for the new era of cardiovascular prevention.

Ramjee V, Eapen DJ, Sperling LS.

Ann N Y Acad Sci. 2012 Apr;1254:106-14. doi: 10.1111/j.1749-6632.2012.06478.x. Review.

PMID:
22548576
20.

Non-HDL C equals apolipoprotein B: except when it does not!

Sniderman A, Williams K, de Graaf J.

Curr Opin Lipidol. 2010 Dec;21(6):518-24. doi: 10.1097/MOL.0b013e32833ee80c. Review.

PMID:
20827192
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk